In response to the evolving needs and expectations of our clients for accelerated IND timelines, Charles River has adopted new standardized reporting timelines. We now offer a fully compiled, audited draft report at 10 weeks post-necropsy for studies up to and including 13 weeks of treatment across all Charles River preclinical facilities. With these globalized processes optimized, a typical IND-enabling program conducted at Charles River is on an accelerated timeline, where all required final reports are delivered at a maximum of 26 weeks from test article receipt (given standard program parameters). This includes allotted time for analytical and bioanalytical method development and validation, repeat dose toxicology in-life and reversal phases (in this example with treatment up to 28 days with a 28-day recovery), standard safety pharmacology battery and genetic toxicology tests.
For your IND guide and full access to our accelerated reporting timelines, including a full-size Gantt chart, please log in to The Source℠. If you are not a member of The Source℠, our new online scientific and educational information center, please click here to register.
For more information about our preclinical capabilities, contact us at askcharlesriver@crl.com.